Rockwell Medical - RMTI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 501.50 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.33
▲ +0.01 (0.76%)

This chart shows the closing price for RMTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rockwell Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMTI

Analyst Price Target is $8.00
▲ +501.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Rockwell Medical in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 501.50% upside from the last price of $1.33.

This chart shows the closing price for RMTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Rockwell Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2022HC WainwrightBoost TargetBuy$8.00Low
1/18/2022HC WainwrightLower TargetBuy$55.00 ➝ $33.00Low
9/7/2021HC WainwrightLower TargetBuy$60.50 ➝ $55.00Low
6/29/2021HC WainwrightReiterated RatingBuy$60.50Medium
2/8/2021HC WainwrightLower TargetBuy$99.00 ➝ $60.50Medium
7/14/2020HC WainwrightReiterated RatingBuy$99.00High
5/19/2020HC WainwrightReiterated RatingBuy$99.00High
4/21/2020HC WainwrightReiterated RatingBuy$99.00Medium
4/7/2020HC WainwrightLower TargetBuy$121.00 ➝ $99.00Low
1/21/2020HC WainwrightReiterated RatingBuy$121.00High
12/2/2019HC WainwrightReiterated RatingBuy$121.00Low
11/11/2019Piper Jaffray CompaniesLower TargetReduce ➝ Overweight$110.00 ➝ $66.00High
10/28/2019HC WainwrightReiterated RatingBuy$121.00Low
6/24/2019Cantor FitzgeraldInitiated CoverageOverweight$121.00Medium
6/24/2019Piper Jaffray CompaniesInitiated CoverageOverweight$110.00 ➝ $110.00Medium
6/19/2019Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformHigh
5/28/2019HC WainwrightSet TargetBuy$132.00High
5/13/2019HC WainwrightInitiated CoverageBuy ➝ Buy$121.00High
3/18/2019Ifs SecuritiesUpgradeOutperform ➝ Strong-BuyHigh
10/19/2018Ifs SecuritiesReiterated RatingStrong-Buy ➝ Outperform$121.00Medium
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Rockwell Medical logo
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Read More

Today's Range

Now: $1.33
Low: $1.30
High: $1.35

50 Day Range

MA: $1.58
Low: $1.27
High: $2.11

52 Week Range

Now: $1.33
Low: $1.17
High: $7.15

Volume

802 shs

Average Volume

102,368 shs

Market Capitalization

$12.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Rockwell Medical?

The following equities research analysts have issued research reports on Rockwell Medical in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for RMTI.

What is the current price target for Rockwell Medical?

1 Wall Street analysts have set twelve-month price targets for Rockwell Medical in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 501.5%. HC Wainwright has the highest price target set, predicting RMTI will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Rockwell Medical in the next year.
View the latest price targets for RMTI.

What is the current consensus analyst rating for Rockwell Medical?

Rockwell Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RMTI will outperform the market and that investors should add to their positions of Rockwell Medical.
View the latest ratings for RMTI.

What other companies compete with Rockwell Medical?

How do I contact Rockwell Medical's investor relations team?

Rockwell Medical's physical mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The company's listed phone number is (248) 960-9009 and its investor relations email address is [email protected] The official website for Rockwell Medical is www.rockwellmed.com. Learn More about contacing Rockwell Medical investor relations.